REG - N4 Pharma PLC - Change of Adviser

N4 PharmaAnnouncement

15/07/2020 07:00

RNS Number : 9917S
  
N4 Pharma PLC
  
15 July 2020
  
 

15 July 2020
 
N4 Pharma plc
 
("N4 Pharma" or the "Company")
 
 
Change of Adviser
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce the appointment of SP Angel Corporate Finance LLP as the Company's Nominated Adviser and Joint Broker, with immediate effect.
 
Management Change
 
The Company also announces that Luke Cairns, previously a Non-Executive Director of the Company, has been appointed to an Executive Director position.  Luke will be overseeing the Company's finance and investor relations activities, thereby allowing Nigel Theobald, Chief Executive Officer, more time to focus on driving the Company's development programmes and potential commercial collaborations. 
 
 
Enquiries:
 



N4 Pharma plc








Nigel Theobald, CEO 


Via Scott PR




Luke Cairns, Executive Director


















SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Joint Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


















Turner Pope Investments (TPI) Limited


Tel: +44(0)20 3657 0050




Joint Broker








Andy Thacker


















Scott PR








Georgia Smith


Tel: +44(0)1477 539 539



 
 
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
APPRIMITMTJBBMM